"BioShield II" Hearing Reveals Continued Division On IP Incentives
This article was originally published in The Pink Sheet Daily
Executive Summary
GPhA should provide more input on its concerns over intellectual property protections in the bill, Sen. Enzi says. Though R&D incentives are needed, a "wild card" exclusivity provision could allow unfair patent extensions, Sen. Schumer argues.